Atogepant Clinical Trials
5 recruitingDrug
Phase 34
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie420 enrolled61 locationsNCT06810505
Recruiting
Phase 3
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Migraine
AbbVie1,300 enrolled149 locationsNCT06241313
Recruiting
Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
AbbVie450 enrolled98 locationsNCT05711394
Recruiting
Phase 3
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Menstrual Migraine (MM)
AbbVie430 enrolled95 locationsNCT06806293
Recruiting
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
MigraineChronic MigraineEpisodic Migraine
AbbVie3,000 enrolled4 locationsNCT06603558